Profile data is unavailable for this security.
About the company
Redx Pharma Plc is a United Kingdom-based clinical-stage biotechnology company. The Company is focused on the discovering and developing of novel, small molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis. The Company’s product pipeline includes RXC004, RXC007 (ROCK2 selective inhibitor) and RXC008. RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme Porcupine, a key activator of Wnt-ligands in the Wnt signaling pathway. Selective ROCK2 inhibitor for the treatment of interstitial lung diseases with an initial study in idiopathic pulmonary fibrosis. RXC007 is a potent, selective and orally active inhibitor that targets Rho-Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2), which sits at a nodal point in cell signaling pathways, central to fibrosis. RXC008 for the treatment of fibrostenotic Crohn’s disease.
- Revenue in GBP (TTM)4.20m
- Net income in GBP-33.16m
- Incorporated2010
- Employees101.00
- LocationRedx Pharma PLCBlock 33, Mereside,, Alderley ParkMACCLESFIELD SK10 4TGUnited KingdomGBR
- Phone+44 162 546 9900
- Fax+44 151 706 4749
- Websitehttps://www.redxpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Arecor Therapeutics PLC | 3.38m | -9.42m | 42.11m | 51.00 | -- | 3.19 | -- | 12.46 | -0.3108 | -0.3108 | 0.1114 | 0.4314 | 0.1805 | -- | 0.7516 | 66,254.90 | -50.32 | -- | -66.40 | -- | -- | -- | -278.81 | -- | 2.28 | -- | 0.0125 | -- | 107.51 | -- | -50.11 | -- | -- | -- |
Venture Life Group PLC | 48.57m | -756.00k | 46.49m | 153.00 | -- | 0.6289 | 7.74 | 0.9571 | -0.0066 | -0.0066 | 0.3635 | 0.5844 | 0.4363 | 2.47 | 3.78 | 317,477.10 | -0.679 | 1.75 | -0.7572 | 2.01 | 38.56 | 40.30 | -1.56 | 4.41 | 1.55 | 1.37 | 0.2375 | 0.00 | 34.24 | 22.33 | -78.35 | -- | 37.59 | -- |
Poolbeg Pharma PLC | 0.00 | -4.89m | 48.25m | 12.00 | -- | 2.91 | -- | -- | -0.0098 | -0.0098 | 0.00 | 0.0331 | 0.00 | -- | -- | 0.00 | -25.02 | -- | -25.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -100.60 | -- | -- | -- |
Celadon Pharmaceuticals PLC | 20.74k | -8.06m | 52.97m | -- | -- | 16.90 | -- | 2,554.12 | -0.1306 | -0.1306 | 0.0003 | 0.0488 | 0.0016 | 267.85 | 0.0248 | -- | -64.68 | -- | -71.16 | -- | -29,080.42 | -- | -40,384.18 | -- | 1.84 | -12.45 | 0.6052 | -- | -- | -- | -- | -- | -- | -- |
Eco Animal Health Group Plc | 88.46m | -1.62m | 56.91m | 228.00 | -- | 0.6978 | 23.61 | 0.6433 | -0.024 | -0.024 | 1.31 | 1.20 | 0.7664 | 1.92 | 3.41 | 387,986.80 | -0.1949 | 6.03 | -0.2645 | 8.02 | 43.05 | 46.41 | -0.2544 | 7.89 | 2.26 | 1.22 | 0.0437 | 55.72 | 3.79 | 4.89 | 246.94 | -35.90 | -4.43 | -- |
e-Therapeutics plc | 475.00k | -8.27m | 65.15m | 38.00 | -- | 1.96 | -- | 137.17 | -0.0154 | -0.0154 | 0.0009 | 0.0568 | 0.0148 | -- | 1.92 | 12,500.00 | -25.79 | -33.25 | -27.10 | -35.11 | 100.00 | 100.00 | -1,741.90 | -1,490.90 | -- | -- | 0.0089 | -- | -0.4193 | -- | -2.53 | -- | 24.22 | -- |
Redx Pharma PLC | 4.20m | -33.16m | 72.93m | 101.00 | -- | 18.72 | -- | 17.36 | -0.099 | -0.099 | 0.0126 | 0.01 | 0.0954 | -- | 135.55 | 41,603.96 | -75.26 | -52.99 | -166.19 | -88.10 | -- | -- | -789.05 | -206.66 | -- | -- | 0.8405 | -- | -77.52 | 100.71 | -84.15 | -- | 8.12 | -- |
Scancell Holdings Plc | 0.00 | -11.32m | 95.10m | 51.00 | -- | -- | -- | -- | -0.0138 | -0.0138 | 0.00 | -0.0102 | 0.00 | -- | -- | 0.00 | -37.31 | -33.32 | -40.52 | -35.82 | -- | -- | -- | -817.98 | -- | -- | 1.73 | -- | -- | -- | -161.24 | -- | 77.85 | -- |
Faron Pharmaceuticals Oy | 0.00 | -26.51m | 96.33m | 40.00 | -- | -- | -- | -- | -0.4095 | -0.4095 | 0.00 | -0.2171 | 0.00 | -- | -- | -- | -287.97 | -213.06 | -- | -963.12 | -- | -- | -- | -- | -- | -12.02 | -- | -- | -- | -- | -7.71 | -- | -16.05 | -- |
Holder | Shares | % Held |
---|---|---|
Redmile Group LLCas of 07 Nov 2023 | 276.89m | 71.18% |
Polar Capital LLPas of 07 Feb 2024 | 21.11m | 5.43% |
Invus Public Equities Advisors LLCas of 07 Nov 2023 | 15.20m | 3.91% |
AXA Investment Managers UK Ltd.as of 16 Mar 2020 | 12.29m | 3.16% |
Hargreaves Lansdown Asset Management Ltd.as of 09 Mar 2020 | 8.45m | 2.17% |
Platinum Investment Management Ltd.as of 08 Mar 2023 | 5.95m | 1.53% |
IG Markets Ltd.as of 01 Feb 2024 | 570.00k | 0.15% |
HSBC Global Asset Management (UK) Ltd.as of 01 Feb 2024 | 139.00k | 0.04% |
Panmure Gordon (UK) Ltd.as of 01 Feb 2024 | 74.00k | 0.02% |
Evelyn Partners Investment Management Services Ltd.as of 01 Feb 2024 | 72.00k | 0.02% |